SLU-PP-332 vs retatrutide explained: how these two unapproved weight-loss compounds differ in mechanism, human trial data, dosing, and side effects.
SLU-PP-332 and retatrutide are two entirely different molecules that get grouped together only because both are discussed as experimental weight-loss agents. SLU-PP-332 is a laboratory ERR agonist studied almost exclusively in mice, while retatrutide is an injectable triple-hormone agonist that has finished phase 2 and is now in phase 3 human trials. Neither compound is FDA-approved for human use.
What Is SLU-PP-332?
SLU-PP-332 is a small-molecule agonist of estrogen-related receptors (ERR alpha, beta, and gamma). It was built as a research tool to test whether activating those receptors could push skeletal muscle toward burning more fat for fuel.
Nearly all published data come from rodents. In mouse studies, the compound has been associated with longer treadmill endurance, higher fatty acid oxidation, and greater energy expenditure without the cardiovascular strain typical of stimulants.
SLU-PP-332 is not approved by the FDA for human use, and no completed human trials have been published. That single fact shapes every other comparison on this page.
What Is Retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly that activates three receptors at once: GLP-1, GIP, and glucagon. It is given as a weekly subcutaneous injection.
In a 2023 phase 2 trial, adults with obesity lost roughly 24% of their body weight on average at the highest dose over 48 weeks. That result makes it one of the most potent weight-loss agents ever measured in a controlled human study.
Retatrutide is not FDA-approved and remains an investigational drug, so the only lawful way to receive it in the United States is through an enrolled clinical trial.
SLU-PP-332 vs Retatrutide: Head-to-Head Comparison
Shorthand searches like slu pp 332 vs reta point to the same underlying question: what actually separates these two compounds? The table below summarizes the practical differences.
| Feature | SLU-PP-332 | Retatrutide |
|---|---|---|
| Compound class | Small-molecule ERR agonist | Peptide triple receptor agonist |
| Receptors targeted | ERR alpha, beta, gamma | GLP-1, GIP, glucagon |
| Proposed mechanism | Raises muscle oxidative capacity | Suppresses appetite, slows gastric emptying, raises energy expenditure |
| Route used in studies | Oral, in animals | Weekly subcutaneous injection |
| Human trial data | None published | Phase 2 complete; phase 3 ongoing |
| FDA status | Not approved, not in human trials | Not approved, investigational |
| Best-documented outcome | Mouse endurance and fat oxidation | About 24% average weight loss at 48 weeks |
Human Data: Where Each Compound Stands
The evidence gap is the largest real difference between these two molecules. Retatrutide has thousands of patient-weeks of placebo-controlled data behind it. SLU-PP-332 has none.
Because no human pharmacokinetic data exist, slu-pp-332 dosage figures circulating online are extrapolated from mouse work and cannot be converted into a safe human equivalent. Claims about slu-pp-332 benefits rest on animal endpoints such as treadmill time and oxygen consumption, not on measured weight loss in people.
Reported slu-pp-332 side effects in animal studies appear limited, but rodent tolerability is a weak predictor of human safety. Retatrutide's profile is better characterized: nausea, vomiting, diarrhea, and constipation are the most common complaints, and modest heart-rate increases have been observed.
Other Compounds People Compare to SLU-PP-332
Retatrutide is not the only molecule weighed against SLU-PP-332. Most alternatives fall into three loose categories.
- Mitochondrial peptides — people searching ss-31 vs slu pp 332 are contrasting a mitochondria-targeted peptide with an ERR agonist.
- Uncouplers — bam 15 vs slu-pp-332 discussions focus on how much energy the compound releases as heat rather than ATP.
- Appetite or fat-mobilization agents — tesofensine vs slu-pp-332 and slu-pp-332 vs tesamorelin pairings mix central appetite effects with peripheral fat release.
Two more pairings surface often. Readers comparing atx 304 vs slu pp 332 are usually asking whether a next-generation ERR agonist improves on the original, while slu-pp-332 vs sr9009 draws attention because both target metabolic machinery instead of appetite.
Newer analogs also get pulled into the conversation. Readers searching slu-pp-915 vs slu-pp-332 are typically asking whether the newer molecule improves bioavailability.
Delivery route matters in these debates too. The slu-pp-332 oral vs injection question exists because human oral bioavailability is unmeasured, and injectable versions have not been tested in people at all.
Safety, Legal Status, and Practical Realities
Neither compound can legally be sold as a dietary supplement for weight loss in the United States. SLU-PP-332 is a research chemical with no approved human pathway, and retatrutide is a prescription drug candidate still under review.
Buying either compound from a non-trial source means accepting unknown purity, unknown dosing, and no regulatory oversight.
Anyone currently taking a GLP-1 or GIP-based medication should not stack it with unapproved research compounds. Drug interactions, cardiac effects, and metabolic shifts from untested combinations are genuinely unknown.
Talk with a licensed healthcare professional before using any investigational compound, and treat forum reports as anecdotes rather than evidence.
Bottom Line
- SLU-PP-332 is an ERR agonist with mouse data only; retatrutide is a triple receptor peptide agonist with phase 3 human data.
- Retatrutide has produced roughly 24% average weight loss in a phase 2 trial; SLU-PP-332 has produced no human weight-loss data at all.
- Neither compound is FDA-approved for human use in the United States.
- Retatrutide requires weekly injection; SLU-PP-332 is typically discussed as an oral research chemical with unknown human absorption.
Frequently Asked Questions
Is SLU-PP-332 the same as retatrutide?
No. SLU-PP-332 is a small-molecule ERR agonist studied in rodents, while retatrutide is an injectable peptide that activates the GLP-1, GIP, and glucagon receptors. They are chemically unrelated and work through completely different pathways.
Has SLU-PP-332 ever been tested in humans?
No completed human trials of SLU-PP-332 have been published. All available efficacy and tolerability data come from animal studies, which means safe human dosing has never been established.
Is retatrutide available for weight loss right now?
Retatrutide is not FDA-approved and can only be obtained legally by enrolling in a clinical trial. Products sold online as retatrutide are unregulated and may contain different or impure substances.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.